Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will host an Investor Conference with analysts and investors on March 23, 2023 in New York City. The event will feature presentations and Q&A sessions with the company's senior leadership team. The conference will be webcast live beginning at 8:00 a.m. ET and will conclude by 12:00 p.m. ET. All interested parties are invited to register and access the webcast here, or visit the Investor Relations section at ElevanceHealth.

Elevance Health to Host Investor Conference

At just over $6 billion, net income was flat compared to the prior year. Elevance is taking close to seven weeks on average to pay out claims.

1 Undervalued Healthcare Stock That's Worth a Second Look

British American Tobacco

Cameco

Enphase Energy

General Motors

Marcus

Phillips 66

With the Federal Reserve perhaps poised to raise benchmark interest rates again, a temptation exists to avoid long-term growth stocks altogether. Should borrowing costs rise sharply, this dynamic would kill expansionary initiatives.

7 Growth Stocks to Consider for Long-Term Portfolio Gains

Elevance Health is among the most dominant players in its industry. The company's dividend obligation is low.

Buy This Undervalued Blue Chip Stock for Tremendous Dividend Growth

INDIANAPOLIS--(BUSINESS WIRE)--Individuals who experience long COVID are at increased risk for a wide range of adverse cardiovascular and pulmonary conditions and mortality, according to a new study published in JAMA Health Forum. The study, led by researchers at the Elevance Health Public Policy Institute, found substantially higher mortality rates for individuals with long COVID than what had been found in previous studies.

Elevance Health Public Policy Institute's study on Long COVID published in JAMA Health Forum Study

Assured Guaranty

Blackrock Inc

BWX Technologies

Commerce Bancshares

Cogent Communications Holdings

Canadian National Railway Company

eBay

Equinix

Evans Bancorp

Exponent

Comfort Systems USA

Genpact

Gaming and Leisure Properties

Home Depot

Jack Henry & Associates

Kforce

Kimberly-Clark

L3Harris

LeMaitre Vascular

Louisiana-Pacific

Northrim BanCorp

Public Service Enterprise Group

Perrigo

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.3% and a median increase of 8.1%.

32 Upcoming Dividend Increases Including 2 Dividend Kings

Arthur J. Gallagher & Co.

New Linde PLC

Microsoft

Targa Resources

Vici Properties

If you're looking for dividend stocks to buy to retire rich, I can help you.  However, it's important to remember that dividend stocks alone aren't the cure-all for retiring rich.

7 Dividend Stocks to Buy to Retire Rich

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?

Why Is Elevance Health (ELV) Down 3.2% Since Last Earnings Report?

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners. BioPlus provides a complete range of specialty pharmacy services for patients living with complex and chronic conditions, such as cancer, multiple sclerosis, hepatitis C, autoimmune diseases, and rheumatology.

Elevance Health Announces Closing of BioPlus Acquisition

Abbott Labs

Accenture Plc

Adobe

Autodesk

Aflac

Applied Materials

Advanced Micro Devices

Amazon

Activision Blizzard

AutoZone

Broadridge Financial

Carrier Global

Caterpillar

Constellation Energy Corp

Cigna

CME Group

Copart

Cintas Corp

Deere & Company

Dollar General

Domino's Pizza

FactSet Research Systems

Fair Isaac

Three companies have been removed from my watchlist and added to the active portfolio. I added four new companies to my watchlist.

Compounders And Dividends: February 2023 Watch List Update

ELV generated outstanding revenue growth, owing to its improving medical membership growth. Despite the expected end of Medicaid's continued coverage, ELV is well-positioned to continue growing.

Elevance Health: Attractive On Its Expansion Catalysts

Centene

Humana

Molina Healthcare

UnitedHealth Group

A proposal for lower-than-expected Medicare Advantage rates in 2024 has sent shares of publicly traded health insurers falling.

Health-insurance stocks drop after Medicare Advantage proposes lower rates for 2024

This company is a leader in a massive and growing industry.

Should You Buy This Steady Dividend Growth Stock?

The giant health insurers each did well last year.

Better Buy: UnitedHealth Group or Elevance Health?

INDIANAPOLIS--( BUSINESS WIRE )--Elevance Health, Inc. (NYSE: ELV) announced today that for the six-month interest period commencing on October 15, 2022, its 2.750% Senior Convertible Debentures due 2042 (the “Debentures”) will accrue contingent interest at a rate of 0.50% per annum of the average trading price of a Debenture for the ten consecutive trading days ended October 14, 2022. Contingent interest, which the Company has determined to be approximately $16.8123 per Note, will be payable on April 15, 2023 to holders of the Debentures as of the April 1, 2023 record date.

Elevance Health's 2.750% Senior Convertible Debentures due 2042 to Accrue Contingent Interest

News for Elevance Health Inc Stock (ELV)